- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
The Guideline Development Group (GDG) at the World Health Organization have advised against using remdesivir as a treatment for COVID-19 patients in hospital. The panel of international experts state that currently there is “no evidence that it improves survival and other important measures” based on data from over 7,000 patients in four international trials.
The GDG acknowledge that the data analysed to date does not prove no benefit of remdesivir, rather that there are greater risks of harm and intensive resources needs to give remdesivir intravenously. Therefore they advise against it being a treatment at this time. They do however support ongoing trials evaluating remdesivir as further evidence is needed on outcomes for specific patient groups.
Full clinical study reports are yet to be published.
The latest version 2 of ‘A living WHO guideline on drugs for COVID-19’ is published in the British Medical Journal [PDF].
Countering Misinformation & Disinformation: Practical Training for Organizations
Practical skills to detect, verify, and respond across an evolving information landscape
Additional data provided by
English
Japanese
